Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure

Circulation

Volumn 110, Issue 21, 2004, Pages 3360-3366

  Hui, Yiqun ^a   Cheng, Yan ^a   Smalera, Isabella ^b   Jian, Wenying ^a   Goldhahn, Lawrence ^a   FitzGerald, Garret A ^a   Funk, Colin D ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Blood pressure; Edema; Endothelium; Leukotrienes; Receptors

Indexed keywords

ANGIOPOIETIN RECEPTOR; LEUKOTRIENE C4; LEUKOTRIENE RECEPTOR; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; PEPTIDOLEUKOTRIENE 1 RECEPTOR; PEPTIDOLEUKOTRIENE 2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA MEDIA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; CALCIUM MOBILIZATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENHANCER REGION; GENE EXPRESSION; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PRESSOR RESPONSE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TRANSGENIC MOUSE;

ANIMALS; BLOOD PRESSURE; CALCIUM SIGNALING; CAPILLARY PERMEABILITY; EAR, EXTERNAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; HYPOTENSION; LEUKOTRIENE C4; LUNG; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NITRIC OXIDE; PASSIVE CUTANEOUS ANAPHYLAXIS; RECEPTORS, LEUKOTRIENE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 9344227345     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000147775.50954.AA     Document Type: Article

References (40)

1. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA. 1979;76:4275-4279.
2. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220;568-575.
3. Coleman RA, Eglen RM, Jones RL, et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:283-285.
4. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol. 2002;64:1549-1557.
5. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197-206.
6. Grayson MH, Korenblat PE. The emerging role of leukotriene modifiers in allergic rhinitis. Am J Respir Med. 2003;2:441-450.
7. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-793.
8. Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999;56:657-663.
9. Maekawa A, Kanaoka Y, Lam BK, et al. Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc Natl Acad Sci USA. 2001;98:2256-2261.
10. Martin V, Sawyer N, Stocco R, et al. Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. Biochem Pharmacol. 2001;62:1193-1200.
11. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-30536.
12. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun. 2000;274:316-322.
13. Nothacker HP, Wang Z, Zhu Y, et al. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000;58:1601-1608.
14. Hui Y, Yang G, Galczenski H, et al. The murine cysteinyl leukotriene 2 (CysLT2) receptor: cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem. 2001;276:47489-47495.
15. Ogasawara H, Ishii S, Yokomizo T, et al. Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution. J Biol Chem. 2002;277:18763-18768.
16. Ortiz JL, Gorenne I, Cortijo J, et al. Leukotriene receptors on human pulmonary vascular endothelium. Br J Pharmacol. 1995;115:1382-1386.
17. Back M, Norel X, Walch L, et al. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol. 2000;401:389-395.
18. Kamohara M, Takasaki J, Matsumoto M, et al. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001;287:1088-1092.
19. Lötzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:e32-e36.
20. Sjöstrom M, Johansson AS, Schröder O, et al. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:e37-e41.
21. Datta YH, Romano M, Jacobson BC, et al. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation. 1995;92:3304-3311.
22. Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther. 1997;281:655-662.
23. Maekawa A, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem. 2002;277:20820-20824.
24. Yang G, Haczku A, Chen H, et al. Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am J Physiol. 2004;286:L992-L1001.
25. Lim YC, Garcia-Cardena G, Allport JR, et al. Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. Am J Pathol. 2003;162:1591-1601.
26. Chen XS, Zhang YY, Funk CD. Determinants of 5-lipoxygenase nuclear localization using green fluorescent protein/5-lipoxygenase fusion proteins. J Biol Chem. 1998;273:31237-31244.
27. Schlaeger TM, Bartunkova S, Lawitts JA, et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA. 1997;94:3058-3063.
28. Labat C, Ortiz JL, Norel X, et al. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther. 1992;263:800-805.
29. Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA. 1981;78:3887-3891.
30. Bochnowicz S, Underwood DC. Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig. Prostaglandins Leukot Essent Fatty Adds. 1995;52:403-411.
31. Di Gennaro A, Carnini C, Buccellati C, et al. Cysteinyl-leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl leukotrienes. FASEB J. 2004;18:842-844.
32. 2+ signaling in the regulation of endothelial permeability. Vasc Pharmacol. 2003;39:173-185.
33. Walch L, Norel X, Gascard JP, et al. Functional studies of leukotriene receptors in vascular tissues. Am J Respir Crit Care Med. 2000;161:S107-S111.
34. Eimerl J, Siren AL, Feuerstein G. Systemic and regional hemodynamic effects of leukotrienes D4 and E4 in the conscious rat. Am J Physiol. 1986;251:H700-H709.
35. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA. 1980;77:4354-4358.
36. Brink C, Dahlen SE, Drazen J, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 2003;55:195-227.
37. Back M, Walch L, Norel X, et al. Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiol Scand. 2002;174:9-15.
38. Pawloski JR, Chapnick BM. Leukotrienes C4 and D4 are potent endothelium-dependent relaxing agents in canine splanchnic venous capacitance vessels. Circ Res. 1993;73:395-404.
39. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res. 1999;43:532-541.
40. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol. 1996;271:C1424-C1437.